Related by context. All words. (Click for frequent words.) 72 sapacitabine 71 MGCD# [001] 71 ganetespib 70 PXD# 69 HGS ETR1 69 Perifosine 68 Cloretazine R VNP#M 68 HGS ETR2 68 vosaroxin 67 eniluracil 67 perifosine 67 INCB# [001] 66 OXi# 66 pralatrexate 66 AP# [003] 66 Panzem R NCD 66 Voreloxin 66 alvespimycin 66 PEG Interferon lambda 66 anti leukemic 66 axitinib 66 Omacetaxine 66 picoplatin 66 GRN#L 66 obatoclax 65 RGB # 65 phase IIb clinical 65 Cloretazine 65 BAY #-# 65 Xanafide 65 glufosfamide 65 RDEA# 65 talactoferrin 65 IMC A# 65 lintuzumab 65 enzastaurin 64 Cloretazine R 64 Cloretazine ® 64 hematological malignancies 64 Amigal 64 palifosfamide 64 Phase Ib 64 AEG# 64 REOLYSIN ® 64 dacetuzumab 64 belinostat 64 Phase Ib II 64 XL# [003] 64 INCB# [002] 64 ELACYT 63 JAK inhibitor 63 AQ4N 63 Marqibo 63 FOLOTYN 63 mapatumumab 63 elotuzumab 63 Archexin 63 celgosivir 63 OncoVEX GM CSF 63 Azixa 63 tesetaxel 63 tanespimycin 63 Phase 2a trial 63 Atiprimod 63 Zerenex 63 registrational 63 Bortezomib 63 Asentar 63 ixabepilone 63 MBP# [001] 63 elesclomol 63 tezampanel 63 MEK inhibitors 63 Pralatrexate 63 aflibercept 63 rNAPc2 62 CoFactor 62 hematologic malignancies 62 HER2 positive metastatic breast 62 Carfilzomib 62 epigenetic therapies 62 CA4P 62 forodesine 62 Albuferon 62 Neuradiab 62 adecatumumab 62 ASONEP 62 PEG SN# 62 anticancer therapy 62 unique alkylating agent 62 HRPC 62 metastatic melanoma 62 dirucotide 62 DAVANAT R 62 YONDELIS 62 Phase 1b 62 VNP#M 62 TOCOSOL Paclitaxel 62 NEUMUNE 62 antitumor activity 62 Panzem R 62 registrational trial 62 ISIS # 62 Phase 2b trial 62 MGCD# [002] 62 PS# [001] 62 depsipeptide 62 T DM1 62 anticancer agents 62 phase Ib 62 MOZOBIL 61 TACI Ig 61 PRTX 61 ZYBRESTAT 61 anticancer agent 61 CR# vcMMAE 61 Allovectin 7 R 61 tivozanib 61 HuMax CD# 61 Azedra 61 OvaRex R 61 HGS# 61 ASA# 61 ridaforolimus 61 Reolysin 61 brentuximab vedotin SGN 61 deforolimus 61 Annamycin 61 oritavancin 61 HCV protease 61 Ceflatonin R 61 MAXY G# 61 Blinatumomab 61 carfilzomib 61 Tamibarotene 61 MEK inhibitor RDEA# 61 otelixizumab 61 Phase 1b trial 61 radiation sensitizer 61 pomalidomide 61 IMGN# 61 torezolid phosphate 61 limiting toxicity 61 FavId 61 MEK inhibitor 61 Amrubicin 61 bardoxolone 61 atacicept 61 Phase #b/#a 61 velafermin 61 KRN# 61 HuMax CD4 61 elacytarabine 61 oral ridaforolimus 61 Phase Ib study 61 TELINTRA 61 Phase 2b clinical 61 XL# XL# 61 IMC #B 61 seliciclib 61 lupus nephritis 61 vascular disrupting agent 61 tesmilifene 61 Phase #/#a trial 61 PRT# 61 CBLC# 61 Tyrima 61 investigational monoclonal antibody 60 romidepsin 60 Bezielle 60 ATL# [001] 60 docetaxel chemotherapy 60 sunitinib malate 60 PLK1 SNALP 60 CEQ# 60 EndoTAG TM -1 60 Protexia R 60 blinatumomab 60 HspE7 60 sorafenib Nexavar 60 Chemophase 60 IMA# 60 Protexia ® 60 confirmatory Phase III 60 CTAP# Capsules 60 PROSTVAC TM 60 XmAb# 60 ularitide 60 ofatumumab 60 Vilazodone 60 phase IIa clinical 60 relapsed multiple myeloma 60 Tanespimycin 60 sunitinib 60 HuLuc# 60 R#/MEM # 60 phenoxodiol 60 HuMax EGFr 60 MDV# 60 DXL# 60 refractory Hodgkin lymphoma 60 CYT# 60 refractory AML 60 Serdaxin 60 investigational humanized monoclonal antibody 60 ANA# 60 preclinical studies 60 randomized Phase 60 Aplidin 60 FOLOTYN ® 60 L BLP# 60 Phenoptin 60 APOPTONE 60 PDX pralatrexate 60 vilazodone 60 mipomersen 60 Dacogen injection 60 Phase Ib clinical 60 polymerase inhibitors 60 bafetinib 60 oral prodrug 60 CCX# 60 ponatinib 60 cutaneous T cell 60 ALN RSV# 60 Fx #A 60 resistant ovarian cancer 60 ISTODAX 60 clofarabine 60 valopicitabine 60 HCD# [002] 60 VEGF Trap 60 Golimumab 60 entinostat 60 CYC# 60 OvaRex ® MAb 60 Allovectin 7 60 cilengitide 60 amrubicin 60 HCV protease inhibitor 60 phase IIb 60 talabostat 60 myelofibrosis 60 AVN# [001] 60 LEP ETU 60 PF # [001] 60 MyVax R 60 Symadex 60 zanolimumab 60 epothilone 59 CUDC 59 TOLAMBA 59 SAR# [004] 59 Telaprevir 59 ENMD 59 PCK# 59 RG# [001] 59 Belinostat 59 relapsed refractory multiple myeloma 59 Allovectin 7 ® 59 MAXY alpha 59 IAP inhibitors 59 ONCONASE 59 #ME# 59 Phase 2a 59 non nucleoside HCV 59 Talabostat 59 hormone refractory prostate cancer 59 favorable pharmacokinetic profile 59 SCH # 59 Exherin TM 59 Triapine R 59 metastatic renal cell carcinoma 59 immunomodulatory 59 ONCONASE R 59 Civacir 59 Restanza 59 SUCCEED trial 59 Triapine 59 brentuximab vedotin 59 DAVANAT ® 59 Sym# 59 CBLB# 59 mitogen activated ERK kinase 59 erlotinib Tarceva ® 59 Ceplene 59 Bicifadine 59 Cetrorelix 59 neratinib 59 Sapacitabine 59 daclizumab 59 sorafenib tablets 59 docetaxel Taxotere R 59 bortezomib 59 PI3K/Akt pathway inhibitor 59 teduglutide 59 Genasense ® 59 oral antiviral 59 EOquin TM 59 tamibarotene 59 ALN PCS 59 sorafenib Nexavar ® 59 custirsen 59 BCX# 59 preclinical 59 omacetaxine 59 Hsp# inhibitor 59 LymphoStat B 59 ADVEXIN 59 EOquin 59 HEPLISAV 59 dasatinib Sprycel ® 59 PEG PAL 59 #D#C# 59 Phase 2a clinical 59 Prochymal 59 bortezomib Velcade R 59 Ambrisentan 59 Phase IIa clinical 59 Ceflatonin 59 Valortim 59 ProLindac 59 IDX# 59 XL# XL# XL# 59 PSN# [002] 59 Phase Ia 59 OMP #M# 59 CD# antibody [001] 59 pivotal Phase 59 GALNS 59 novel anticancer 59 TRV# [001] 59 pertuzumab 59 randomized Phase 2b 59 cell lymphoma CTCL 59 Phase 2b study 59 Randomized Phase 59 vemurafenib 59 APF# 59 pharmacokinetic PK study 59 Zybrestat 59 GMX# 59 nonclinical studies 59 heavily pretreated 59 fosbretabulin 59 vascular disrupting agents 59 satraplatin 59 anticancer compound 59 investigational drug 59 bevacizumab Avastin ® 59 refractory acute myeloid 59 pan HDAC inhibitor 59 HCV protease inhibitors 59 untreated de novo 59 MNTX 59 pivotal Phase III 59 SILENOR TM 59 Plicera 59 Elotuzumab 58 Phase IIb clinical trials 58 monotherapy 58 Exelixis XL# 58 AEGR 58 lymphoma CTCL 58 Phase III clinical 58 Seliciclib 58 Azedra TM 58 hematological cancers 58 Revlimid lenalidomide 58 Icatibant 58 Phase IIb clinical 58 Valortim R 58 PRX # 58 tezampanel NGX# 58 histone deacetylase HDAC inhibitor 58 Valortim ® 58 Traficet EN 58 veltuzumab 58 Menerba 58 Lenocta 58 AEZS 58 selective androgen receptor modulator 58 Clolar ® 58 Stimuvax R 58 Alocrest 58 galiximab 58 bendamustine 58 Glufosfamide 58 huC# DM4 58 Phase #b/#a clinical 58 Curaxin CBLC# 58 Dasatinib 58 nucleoside 58 proteasome inhibitor 58 refractory multiple myeloma 58 Hematide ™ 58 NGX# 58 TELCYTA 58 bavituximab 58 liposomal formulation 58 HDAC Inhibitor 58 trastuzumab DM1 T DM1 58 antibody MAb 58 Abiraterone acetate 58 TYZEKA 58 JAK2 inhibitor 58 tolerability profiles 58 dimebon 58 Sulonex TM 58 ALN VSP 58 pegloticase 58 Targretin 58 NXL# 58 alkylating agent 58 indibulin 58 Apoptone 58 TREANDA 58 Phase 2b 58 Prodarsan ® 58 ON #.Na 58 generation Hsp# inhibitor 58 methylnaltrexone 58 investigational compound 58 Phase IIB 58 dose escalation 58 Phase IIb trials 58 Phase IIb trial 58 castration resistant prostate cancer 58 MAGE A3 ASCI 58 thymalfasin 58 NVA# 58 Fibrillex TM 58 Genz # 58 Zerenex ™ 58 alvimopan 58 2 methoxyestradiol 58 immunomodulator 58 Gemzar ® 58 dexanabinol 58 eculizumab 58 nucleoside reverse transcriptase inhibitor 58 LY# [003] 58 Deforolimus 58 decitabine 58 Taxotere R 58 Tesetaxel 58 Virulizin R 58 Clofarabine 58 maribavir 58 bortezomib Velcade 58 metastatic castration resistant 58 PDE4 inhibitor 58 XL# XL# XL# XL# 58 solid tumors 58 Junovan 58 Viramidine 58 temsirolimus 58 lomitapide 58 Personalized Immunotherapy 58 Stedivaze 58 Tarvacin TM 58 Genasense 58 velafermin belinostat 58 LibiGel ® 58 Exelixis compounds 58 leading oral taxane 58 azacitidine 58 Xcytrin 58 JAK1 58 paclitaxel Taxol 58 vismodegib 58 Zolinza 58 CRMD# 58 mertansine 58 Proxinium TM 58 TNFerade 58 PKC# 58 TAFA# 58 ruxolitinib 58 Cinryze ™ 58 ZADAXIN 58 antithrombotic 58 mRCC 58 dose cohorts 57 generation purine nucleoside 57 rFIXFc 57 ALN TTR# 57 Cloretazine VNP#M 57 Genasense ® oblimersen 57 Tarvacin 57 phase IIb trial 57 pharmacodynamic PD 57 TRO# 57 Aflibercept 57 TMC# [001] 57 myelodysplastic syndromes MDS 57 VELCADE 57 MKC# PP 57 Darinaparsin 57 vidofludimus 57 cytarabine 57 HQK 57 Laquinimod 57 rALLy clinical trial 57 vandetanib 57 AAG geldanamycin analog 57 LibiGel Phase III 57 GED aPC 57 Anthim 57 NKTR 57 apoptosis inducer 57 Riquent 57 lenalidomide Revlimid R 57 phase IIa 57 CXB# 57 immune modulation 57 PrevOnco 57 vinorelbine 57 DermaVir Patch 57 Specifid 57 Telintra 57 ulimorelin 57 Phase 1a clinical 57 Thiovir 57 Pivotal Phase III 57 Aurora kinase 57 nucleoside analog 57 ipilimumab 57 Triolex 57 lumiliximab 57 viral kinetic 57 ZYBRESTAT fosbretabulin 57 Factor VIIa 57 ongoing Phase 1b 57 Guanilib 57 CB2 selective receptor agonist 57 refractory indolent non 57 taxanes 57 Hsp# inhibitors 57 BRAF inhibitor 57 refractory chronic lymphocytic 57 CLORETAZINE TM VNP#M 57 OncoVEX 57 Pivotal Phase 57 Romidepsin 57 IRX 2 57 Phase #b/#a trial 57 rALLy trial 57 Tezampanel 57 evaluating tivozanib 57 Panzem 57 LymphoStat B belimumab 57 cabozantinib 57 TMC# [002] 57 orally bioavailable 57 temozolomide 57 CCR5 antagonist 57 panitumumab 57 Phase IIb 57 evaluating Xcytrin 57 NEUGENE 57 GLP toxicology studies 57 angiogenesis inhibitor 57 Phase Ib clinical trials 57 vorinostat 57 PROVENGE 57 Neulasta ® 57 L MTP PE 57 Tarceva TM 57 Homspera 57 dextromethorphan quinidine 57 compound PMX # 57 seliciclib CYC# 57 Talactoferrin 57 OMAPRO 57 phase 2a 57 sorafenib 57 posaconazole 57 triphendiol 57 Ozarelix 57 PMX # 57 XYOTAX 57 brostallicin 57 cancer immunotherapies 57 dalbavancin 57 preclinical efficacy 57 UPLYSO 57 Dapagliflozin 57 endothelin receptor antagonists 57 aflibercept VEGF Trap 57 CRLX# 57 dose escalation Phase 57 visilizumab 57 SUTENT 57 Onrigin TM 57 sodium glucose cotransporter 57 immunotherapeutic 57 SPRYCEL ® 57 Fodosine 57 XYOTAX TM 57 Vitaxin 57 lesinurad 57 CYT# potent vascular disrupting 57 Onconase 57 Phase IIa 57 confirmatory Phase 3 57 REOLYSIN R 57 HSP# inhibitor 57 ALKS 57 leukemia AML 57 nab paclitaxel 57 albinterferon alfa 2b 57 Debio 57 nicotinic alpha 7 57 MVA BN R 57 adipiplon 57 VAPRISOL 57 delta isoform 57 IND enabling 57 AZD# 57 Taxotere ® 57 kinase inhibitor 57 metastatic colorectal cancer 57 HCV SPRINT 57 ara C 57 Vion Pharmaceuticals 57 chemotherapy induced neutropenia 57 ZK EPO 57 Androxal TM 57 eltrombopag 57 vicriviroc 57 teriflunomide 57 Mipomersen 57 lorvotuzumab mertansine 57 Protectan CBLB# 57 Phase 2a clinical trials 57 cytotoxic chemotherapy 56 refractory gout 56 dasatinib 56 TBC# 56 histone deacetylase inhibitor 56 Stimuvax 56 danoprevir 56 ImmunoVEX HSV2 56 MOR# 56 MGd 56 Troxatyl 56 RIGScan CR 56 tyrosine kinase inhibitor 56 candidate CRLX# 56 Enzastaurin 56 NPC 1C 56 OHR/AVR# 56 rindopepimut 56 Dalbavancin 56 Corlux 56 trabectedin 56 Inhalation Solution 56 Hsp# Inhibitor 56 telomerase therapeutic 56 gemcitabine Gemzar ® 56 CTCE 56 Erlotinib 56 imetelstat 56 NSCLC 56 chemotherapeutic agent 56 docetaxel Taxotere ® 56 Epothilones 56 PANVAC VF 56 telaprevir 56 immune stimulatory 56 OPAXIO 56 demonstrated antitumor activity 56 anticancer therapies 56 bicifadine 56 HGS ETR1 mapatumumab 56 alagebrium 56 erlotinib Tarceva 56 Phase 1b clinical 56 Nexavar ® 56 anidulafungin 56 Telcyta 56 humanized anti 56 Phase IIa trial 56 chemotherapeutic agents 56 selective kinase inhibitor 56 sodium Injection 56 APTIVUS r 56 synthetic retinoid 56 targeting CD# 56 histamine dihydrochloride 56 Pimavanserin 56 BARACLUDE R 56 protein kinase inhibitor 56 Taxotere chemotherapy 56 Cannabinor 56 BRIM2 56 EGFR expressing mCRC 56 uric acid lowering 56 SinuNase TM 56 pharmacokinetic PK 56 Vectibix 56 Ophena TM 56 Fludara 56 XL# anticancer compounds 56 TORISEL 56 ALN TTR 56 ZOLINZA 56 proteasome inhibitors 56 SinuNase 56 FTY# 56 recurrent ovarian cancer 56 gefitinib Iressa 56 Epratuzumab 56 Onrigin 56 Cotara 56 initiate Phase Ib 56 PNP inhibitor 56 HER2 positive breast cancer 56 Phase III 56 lapatinib Tykerb 56 PLX# 56 Cleviprex TM clevidipine 56 polymerase inhibitor 56 Aplidin R 56 farletuzumab 56 AEOL # 56 PSMA ADC 56 refractory PTCL 56 Oritavancin 56 Virulizin ® 56 mifamurtide 56 CD# monoclonal antibody 56 MAP# 56 darinaparsin 56 taxane 56 isoform selective 56 Phase III Pivotal 56 Phase III clinical trials 56 Temsirolimus 56 Celator 56 TRISENOX 56 Viprinex 56 Alpharadin 56 Actilon 56 Phase 2b Clinical Trial 56 EFAPROXYN 56 DAVANAT 56 CORT # 56 Acute Myeloid Leukemia AML 56 personalized immunotherapy 56 BiTE antibody 56 ELND# 56 APPRAISE 56 CIMZIA TM 56 receptor tyrosine kinase inhibitor 56 Defibrotide 56 DOXIL 56 Pafuramidine 56 Opexa 56 TRAIL receptor antibodies 56 CD NP 56 squalamine 56 panobinostat 56 Urocidin 56 darusentan 56 MGN# 56 Sorafenib 56 zalutumumab 56 multicenter Phase 56 GAP #B# 56 SNT MC# 56 Aclidinium 56 immune modulators 56 sodium thiosulfate STS 56 PhosLo 56 apricitabine ATC 56 Genasense oblimersen sodium Injection 56 Genitope Corporation 56 PIX# [002] 56 APD# 56 metaglidasen 56 rituximab 56 Panzem NCD 56 REP# 56 ITMN 56 IND submission 56 small molecule chemotherapeutic 56 AMD# [003] 56 BioNumerik 56 thalidomide Thalomid 56 trastuzumab Herceptin R 56 IIa trial 56 Onco TCS 56 Solazed TM 56 Telavancin 56 maximally tolerated dose 56 RH1 56 superficial bladder cancer 56 Immunotherapeutic 56 Cinryze TM 56 Ofatumumab 56 Maribavir 56 iclaprim 56 urocortin 2 56 Phase IIIb clinical 56 mGluR5 NAM 56 placebo controlled Phase 56 Methylnaltrexone 56 metastatic HRPC 56 midstage clinical 56 chronic lymphocytic leukemia CLL 56 Imprime PGG 56 REOLYSIN 56 Arimoclomol 56 oral deforolimus 56 GSK # 56 Cethromycin 56 LHRH antagonists 55 PREOS 55 abiraterone acetate 55 multiple ascending dose 55 EndoTAGTM 1 55 IV metastatic melanoma 55 Revimmune 55 iSONEP 55 6R BH4 55 investigational compounds 55 platinum refractory 55 anti TNF alpha 55 antiviral activity 55 nucleoside analogue 55 riociguat 55 Lisofylline LSF 55 ozarelix 55 pradefovir 55 raltegravir 55 THALOMID 55 cannabinor 55 Leukine 55 Copegus ribavirin 55 Tasimelteon 55 MAA submission 55 targeted radiotherapeutic 55 lintuzumab SGN 55 Shigamabs ® 55 AKT inhibitor 55 leukemia CLL 55 SparVax TM 55 Elesclomol 55 EVIZON TM squalamine lactate 55 ALIMTA 55 Lovaxin C 55 Angiocept 55 subcutaneous formulation 55 Nanobody 55 ARRY # 55 ARRY 55 daptomycin 55 Bronchitol 55 pharmacokinetic interactions 55 QLT# 55 INGN 55 investigational pan BCR 55 ThermoDox R 55 Romiplostim 55 Onalta 55 Brentuximab Vedotin SGN 55 Fabry Disease 55 Hedgehog Pathway Inhibitor 55 TPI ASM8 55 TRIOLEX 55 preclinically 55 EGFR inhibitors 55 nucleoside analogs 55 Insegia 55 TLK# 55 anticancer 55 biologic therapy 55 initiate Phase 1b 55 ancrod 55 Perforomist ™ Inhalation Solution 55 ATL/TV# 55 metastatic hormone refractory 55 NP2 Enkephalin 55 Enobia 55 immunomodulatory therapy 55 ACZ# 55 elvucitabine 55 Evoltra ® 55 MYCAMINE 55 TYKERB 55 Indibulin 55 PROSTVAC VF 55 KNS # 55 Acute Myeloid Leukemia 55 somatostatin analogue 55 AMN# [001] 55 ocrelizumab 55 refractory CTCL 55 molecularly targeted 55 Panitumumab 55 cancer mCRC 55 PSN# [001] 55 tumor vascular disrupting 55 Trofex 55 MyVax 55 topotecan 55 investigational HCV polymerase 55 varespladib 55 nitazoxanide 55 eprotirome 55 cediranib 55 orally administered inhibitor 55 Phase 1a 55 estramustine 55 DR Cysteamine 55 RLY# 55 viral kinetics 55 JVRS 55 compound INCB# 55 Tarceva erlotinib 55 Squalamine 55 bosutinib 55 BLA filing 55 DU #b 55 Apaziquone 55 Elagolix 55 Clolar 55 bazedoxifene 55 preclinical toxicology 55 rFVIIIFc 55 small molecule defensin 55 BiovaxID 55 Androxal ® 55 clevidipine 55 REG1 55 microtubule targeting 55 ANYARA 55 OMNARIS HFA 55 integrase inhibitor 55 RSD# 55 IL# PE#QQR 55 TLR9 agonist 55 Vandetanib 55 VQD 55 ProLindac TM 55 Alzhemed TM 55 BXT # 55 pharmacokinetics pharmacodynamics 55 PEGPH# 55 telaprevir VX 55 Trastuzumab 55 idarubicin 55 R sorafenib tablets 55 ANAVEX #-# [003] 55 DPX Survivac 55 Acute Radiation Syndrome ARS 55 gemcitabine 55 StaphVAX 55 myeloproliferative diseases 55 cutaneous T 55 GSK# [002] 55 bevacizumab Avastin 55 Phase III randomized controlled 55 GSK# [001] 55 midstage trials 55 siRNA therapeutics 55 radezolid 55 bevirimat 55 anti angiogenic agents 55 ZADAXIN ® 55 TG# [001] 55 cetuximab Erbitux 55 Cushing Syndrome 55 mocetinostat MGCD# 55 pafuramidine 55 Adalimumab 55 Omacetaxine mepesuccinate 55 castrate resistant prostate cancer 55 CD# CEA 55 Antiangiogenic 55 dasatinib Sprycel 55 calcineurin inhibitors 55 BZL# 55 non nucleoside inhibitor 55 elagolix 55 acute myeloid leukemia AML 55 administered subcutaneously 55 tofacitinib 55 oxymorphone ER 55 MLN# 55 ONTAK 55 carboplatin 55 dose escalation trial 55 Genasense R oblimersen 55 dose cohort 55 Poly ICR 55 Soliris TM eculizumab